{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:24:56Z","timestamp":1791894296179,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/mcg.0b013e318188947c","type":"journal-article","created":{"date-parts":[[2009,7,14]],"date-time":"2009-07-14T07:26:50Z","timestamp":1247556410000},"page":"680-685","source":"Crossref","is-referenced-by-count":97,"title":["Combination Treatment With Octreotide, Midodrine, and Albumin Improves Survival in Patients With Type 1 and Type 2 Hepatorenal Syndrome"],"prefix":"10.1097","volume":"43","author":[{"given":"Catherine","family":"Skagen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Einstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Lucey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gines","year":"1993","journal-title":"Gastroenterology"},{"key":"R2-14-20210305","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"R3-14-20210305","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.20687","article-title":"MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation","volume":"41","author":"Alessandria","year":"2005","journal-title":"Hepatology"},{"key":"R4-14-20210305","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gines","year":"2003","journal-title":"Lancet"},{"key":"R5-14-20210305","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"R6-14-20210305","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1053\/gast.2002.33575","article-title":"Hepatorenal syndrome in cirrhosis: pathogenesis and treatment","volume":"122","author":"Arroyo","year":"2002","journal-title":"Gastroenterology"},{"key":"R7-14-20210305","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"R8-14-20210305","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"R9-14-20210305","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R10-14-20210305","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1373\/clinchem.2005.0525144","article-title":"Recommendations for improving serum creatinine measurement: a report from the laboratory working group of the National Kidney Disease Education Program","volume":"52","author":"Myers","year":"2006","journal-title":"Clin Chem"},{"key":"R11-14-20210305","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/00007890-199102000-00030","article-title":"Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome\u2014experience in 300 patients","volume":"51","author":"Gonwa","year":"1991","journal-title":"Transplantation"},{"key":"R12-14-20210305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"R13-14-20210305","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"R14-14-20210305","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1053\/gast.2002.32364","article-title":"Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study","volume":"122","author":"Moreau","year":"2002","journal-title":"Gastroenterology"},{"key":"R15-14-20210305","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0168-8278(98)80151-7","article-title":"Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome","volume":"29","author":"Hadengue","year":"1998","journal-title":"J Hepatol"},{"issue":"4","key":"R16-14-20210305","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"R17-14-20210305","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R20-14-20210305","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1365-2036.2006.03086.x","article-title":"Meta-analysis: terlipressin therapy for the hepatorenal syndrome","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-14-20210305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"Gulberg","year":"1999","journal-title":"Hepatology"},{"key":"R22-14-20210305","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0168-8278(96)80297-2","article-title":"Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome","volume":"25","author":"Salo","year":"1996","journal-title":"J Hepatol"},{"key":"R23-14-20210305","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"R24-14-20210305","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"R25-14-20210305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology"},{"key":"R26-14-20210305","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"R27-14-20210305","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1053\/j.ajkd.2003.08.017","article-title":"Prediction of GFR in liver transplant candidates","volume":"42","author":"Skluzacek","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004836-200908000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T23:48:47Z","timestamp":1739231327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-200908000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318188947c","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}